Fast Track designation

Related by string. Fast Track Designation * faster . Faster . FAST . fasting : fast paced equity . Fast Pitch . Muslim fasting . Fast Track / tracking . tracked . Tracking . Tracks : Off Track Betting . Pacific Epoch tracks TMT . Short Track . tracks EVERY failure / designations . Designation . Designations : Orphan Drug Designation . Orphan Drug designation . enemy combatant designation * *

Related by context. All words. (Click for frequent words.) 78 Fast Track Designation 73 Orphan Drug status 72 Orphan Drug Designation 70 Orphan Drug designation 70 orphan designation 67 Orphan Drug Status 66 orphan drug 66 Orphan Status 66 Fast Track Status 66 Orphan Designation 65 Orphan Drug designations 65 Orphan Medicinal Product 65 Fast Track designations 64 orphan medicinal product 64 Biologics License Application BLA 63 MAA submission 63 Priority Review 62 investigational humanized monoclonal antibody 62 registrational 62 Fibrillex TM 62 Application BLA 62 Firazyr 62 Orphan designation 62 BLA submission 61 OMP designation 61 pseudobulbar affect PBA 61 Investigational Device Exemption 61 Orphan Drug 61 Biologics License Application 61 Granted Orphan Drug 60 FOLOTYN ® 60 Cinryze TM 60 Pivotal Phase III 60 Severe VOD 60 Torisel 60 Marketing Authorization Application MAA 60 FDA Orphan Drug 60 Pivotal Trial 60 alvimopan 60 severe gastroparesis 60 BENLYSTA ® 60 BLA filing 60 sNDA 60 severe hypercholesterolemia 59 ONCONASE 59 Marketing Authorization Application 59 Receives Orphan Drug Designation 59 FDA Approvable Letter 59 Accelerated Approval 59 CryoSeal FS System 59 talactoferrin 59 eltrombopag 59 phase IIb trial 59 supplemental Biologics License Application 59 oral ridaforolimus 59 Rhucin ® 59 ATryn R 59 IMA# 59 Evoltra ® 59 Application MAA 59 Soliris TM eculizumab 59 TORISEL 59 registrational trial 59 Entereg R 59 Vandetanib 59 ATryn ® 59 FDA Accepts 59 systemic immunosuppressive drugs 59 MyVax R 59 Phase 2b Clinical Trial 59 MAGE A3 ASCI 59 Phase III Clinical Trial 59 granted orphan 59 cutaneous T 59 phase IIb clinical 59 confirmatory Phase 3 59 phase IIa clinical 59 Cladribine Tablets 59 ENTEREG ® 58 Zenvia ™ 58 maribavir 58 Phenoptin 58 OMNARIS HFA 58 Iluvien ® 58 Zerenex 58 PROMACTA 58 lymphoma CTCL 58 Voraxaze 58 investigational therapies 58 Receives Fast Track 58 LUVENIQ 58 vandetanib 58 Approvable Letter 58 Icatibant 58 Dupuytren Contracture 58 Act PDUFA date 58 Phase IIb Trial 58 Phase IIb Clinical Trial 58 Microplasmin 58 GALNS 58 PANVAC VF 58 Special Protocol Assessment 58 PNP inhibitor 58 Archexin 58 OMAPRO 58 Cellegesic 58 RANK Ligand inhibitor 58 SNT MC# 58 Octreolin 58 lucinactant 58 confirmatory Phase III 58 dextromethorphan quinidine 58 tezampanel 58 Complete Response 58 Civacir 58 CytoFab 58 Noxafil 58 Meets Primary Endpoint 57 Cimzia TM 57 Panzem R 57 ZEGERID Chewable Tablets 57 Ceflatonin 57 Zelrix 57 rilonacept 57 Completes Patient Enrollment 57 Marketing Authorisation Application 57 Rhucin ® recombinant 57 Phase III pivotal 57 Azedra 57 Receives Orphan Drug 57 oncology indications 57 generation purine nucleoside 57 cutaneous T cell 57 drug ISA# 57 Treatment IND 57 Dacogen injection 57 Kuvan R 57 FDA Complete Response 57 tamibarotene 57 KIACTA ™ 57 PDE4 inhibitor 57 application sNDA 57 Somatuline Depot 57 prGCD 57 RoACTEMRA 57 post menopausal osteoporosis 57 Marketing Authorization 57 Opterone R 57 novel histone deacetylase 57 AA amyloidosis 57 forodesine 57 oxypurinol 57 Marqibo 57 FDA approvable letter 57 NDA Submission 57 Mepact 57 Amrubicin 57 PEGylated interferon beta 1a 57 IND Investigational New 57 SYCREST 57 HepeX B 57 octreotide implant 57 ARIKACE ™ 57 ACTEMRA 57 Luveniq 57 ADP receptor antagonist 57 OMAPRO ™ 57 ketolide antibiotic 57 ADVEXIN p# therapy 57 REVLIMID lenalidomide 57 sBLA 57 Neuromodulation System 57 Biologic License Application 57 Pazopanib 57 hoFH 57 velaglucerase alfa 57 TEMODAL 57 Amigal 57 Nimotuzumab 57 Neurodex 57 Evoltra TM 57 Alvesco R 57 Marketing Authorisation 57 diabetic neuropathic pain 57 ZOLINZA 57 tafamidis 57 PEG SN# 57 PDUFA date 57 ruxolitinib 57 Augment Injectable 57 Allovectin 7 57 Aurexis 57 Trobalt 57 sapropterin dihydrochloride 57 Phase III clinical 57 IND submission 56 Romiplostim 56 Esbriet ® 56 Patient Enrollment 56 GTC recombinant human 56 Biological License Application 56 Phase IIa trials 56 Soliris eculizumab 56 Personalized Immunotherapy 56 Diabetic Macular Edema 56 vitreoretinal disorders 56 vemurafenib 56 Allovectin 7 R 56 tiapamil 56 Arzerra ofatumumab 56 Stedivaze 56 BiovaxID TM 56 HuMax EGFr 56 Bronchitol 56 IL# PE#QQR 56 proprietary transdermal patch 56 OLpur TM H2H 56 Ofatumumab 56 Onalta ™ 56 Intravenous CP 56 albiglutide 56 taliglucerase alfa 56 rNAPc2 56 oral prodrug 56 #D#C# 56 Besivance 56 elotuzumab 56 BRAF inhibitor 56 CRMD# 56 receptor tyrosine kinase inhibitor 56 L MTP PE 56 Pivotal Phase 56 Belimumab 56 HCV protease inhibitor 56 ThermoDox ® 56 LymphoStat B belimumab 56 SUPPRELIN R LA 56 Cutaneous T 56 Phase IIa trial 56 NDA submission 56 CINTREDEKIN BESUDOTOX 56 vinorelbine emulsion 56 Aerosurf 56 aerosolized AAT 56 AzaSite Plus 56 IIa trial 56 Kynapid 56 Phase IIIb clinical 56 PLK1 SNALP 56 Lucanix R 56 HepeX B TM 56 humanized monoclonal antibody 56 non constipation irritable 56 IMGN# 56 Biologic License Application BLA 56 New Drug Application 56 ixabepilone 56 acetonide FA 56 Phase 2a 56 Linjeta TM 56 Phase #b/#a clinical 56 Phase III Trial 56 Anturol TM 56 catheter occlusion 56 Government Qualifying Therapeutic 56 Phase IIb trials 56 RAPTIVA 56 Pralatrexate 56 Folotyn 56 QNEXA 56 FDA Modernization Act 56 Kepivance 56 ecallantide 56 subcutaneous formulation 56 vidofludimus 56 Zingo TM 56 CEQ# 56 Raptiva ® 56 Aryplase 56 oral nucleoside analogue 56 Initiates Phase II 56 formerly LymphoStat B 56 Traficet EN 56 Initiates Enrollment 56 Phase IIIb study 56 MAXY alpha 56 Ganite ® 56 M Enoxaparin 56 Surfaxin LS 56 histone deacetylase HDAC inhibitor 56 hypoxia activated prodrug 56 huC# DM4 56 ALN TTR 56 dalbavancin 56 pivotal Phase III 56 AzaSite Xtra 56 granted Orphan Drug 56 Angiox R 56 GRALISE 56 lintuzumab SGN 56 VitiGam TM 56 Evoltra 56 FIRAZYR 56 homozygous familial hypercholesterolemia 56 Fodosine 56 diarrhea predominant irritable 56 NEUMUNE 55 investigational pan BCR 55 BYETTA ® 55 Rhucin R 55 lomitapide 55 Advagraf 55 Zenvia Phase III 55 Raptiva R 55 Phase 2a trial 55 Vilazodone 55 Presents Positive 55 Pirfenidone 55 REPEL CV 55 granted Ortec 55 tramiprosate ALZHEMED TM 55 atacicept 55 novel oral anticoagulant 55 PREOS R 55 relapsing forms 55 Plicera 55 Resten NG 55 metastatic hormone refractory 55 Troxatyl 55 ezogabine 55 dirucotide 55 oxymorphone ER 55 Drug Eluting Stent System 55 terlipressin 55 Mutual Recognition Procedure 55 LEUKINE 55 Files Investigational 55 USFDA approval 55 CHMP recommendation 55 XGEVA 55 cell lymphoma CTCL 55 Azixa 55 Tanespimycin 55 Tarceva TM 55 UPLYSO 55 Omigard 55 Liprotamase 55 PROVENGE ® 55 Investigational Device Exemption IDE 55 adult chronic ITP 55 NEBIDO R 55 tumor lysis syndrome 55 romidepsin 55 Benlysta belimumab 55 HoFH 55 Actemra tocilizumab 55 unstable angina UA 55 liver resection surgeries 55 Pixantrone 55 tanespimycin 55 HepaGam B 55 OHR/AVR# 55 Iluvien 55 Junovan 55 6R BH4 55 human C1 inhibitor 55 MAb therapy 55 TYZEKA 55 opioid induced bowel dysfunction 55 CCR9 antagonist 55 VIVITROL ® 55 Ganite R 55 Completes Enrollment 55 IgG1 monoclonal antibody 55 chronic idiopathic thrombocytopenic purpura 55 StaphVAX R 55 candidate XP# 55 Phase IIb clinical trials 55 lupus nephritis 55 Sapacitabine 55 TNF Tumor Necrosis Factor 55 gastrointestinal disorders characterized 55 SURFAXIN 55 AVASTIN 55 Pafuramidine 55 markets HP Acthar 55 Crofelemer budesonide foam 55 Entereg TM 55 reslizumab 55 Dyloject TM 55 autologous cellular immunotherapy 55 SILENOR 55 Complete Response letter 55 Phase IIa clinical trials 55 histamine dihydrochloride 55 GED aPC 55 amrubicin 55 Vicinium TM 55 dasatinib Sprycel ® 55 Gamunex C 55 refractory Hodgkin lymphoma 55 SAR# [004] 55 Manja Bouman CEO 55 pralatrexate 55 evaluating pirfenidone 55 ularitide 55 Teflaro 55 SANVAR 55 Oracea TM 55 Aviptadil 55 DC Bead 55 MabCampath 55 acute peripheral arterial 55 BioSTAR R 55 StaphVAX 55 Investigational 55 Receives Positive Opinion 55 TELINTRA 55 GW# [003] 55 XmAb# 55 Pivotal Study 55 Brentuximab Vedotin SGN 55 huN# DM1 55 Orazol 55 Behcet uveitis 55 methylnaltrexone 55 molecular imaging radiopharmaceutical 55 oropharyngeal candidiasis OPC 55 Zenpep 55 myelofibrosis 55 Evoltra R 55 FROVA 55 NOXAFIL 55 IRX 2 55 Bezielle 55 Promacta 55 ARCOXIA 55 Orathecin 55 intravenous iclaprim 55 topically applied SEPA 55 ThermoDox R 55 recombinant biopharmaceutical 55 sunitinib malate 55 anticancer compound 55 Restanza 55 PROMACTA ® 55 ALN PCS 55 Solazed ™ 55 vosaroxin 55 heterozygous FH 54 refractory chronic lymphocytic 54 non metastatic osteosarcoma 54 XIAFLEX ™ 54 Initiates Phase 54 FACTIVE R gemifloxacin 54 opioid induced constipation OIC 54 TORISEL TM 54 DexaSite 54 Istodax 54 Tasimelteon 54 DPX Survivac 54 Xanafide 54 hypereosinophilic syndrome 54 dihydrochloride Tablets 54 MOZOBIL 54 ARIKACE 54 acyclovir Lauriad R 54 paclitaxel poliglumex 54 BRILINTA 54 POSIDUR TM ELADUR TM 54 injectable enzyme 54 ACOMPLIA R 54 ILUVIEN ® 54 post herpetic neuralgia PHN 54 VISICOL R 54 Bafetinib 54 Efficacy Results 54 HFA MDI 54 PrevOnco ™ 54 Zebinix R 54 Unit Dose Budesonide 54 investigational antiplatelet agent 54 MKC# MKC# PP 54 HuLuc# 54 TAXUS Element Stent System 54 Plenaxis R 54 clofarabine 54 Sylvie Gregoire President 54 pediatric Crohn disease 54 panitumumab Vectibix 54 Prodarsan R 54 Ketotransdel 54 Pivotal Clinical Trial 54 Friedreich Ataxia FRDA 54 Prodarsan 54 LymphoStat B 54 ofatumumab 54 ALN TTR# 54 pediatric exclusivity 54 EOquin 54 Humanitarian Device Exemption 54 post operative ileus 54 BENLYSTA 54 Diamyd ® 54 Kit CD# positive 54 II Clinical Trial 54 Virulizin R 54 commercialize oritavancin 54 herpetic keratitis 54 delivers fluocinolone acetonide FA 54 Biologics Licensing 54 Zalbin 54 Initiate Clinical Trial 54 ASG 5ME 54 Panzem R NCD 54 Elagolix 54 Factor VIIa 54 DORIBAX 54 Mimpara 54 dirucotide MBP# 54 Cethromycin 54 Retacrit 54 Preotact 54 eprodisate Fibrillex TM 54 Phase 2b trial 54 rheumatoid arthritis psoriatic arthritis 54 relapsed refractory multiple myeloma 54 rALLy clinical trial 54 MPS VI 54 Phase Ib 54 SinuNase 54 TOCOSOL Paclitaxel 54 Febuxostat 54 Genasense ® 54 HuMax CD4 54 BRIM2 54 highly purified pasteurized 54 relapsing multiple sclerosis 54 PRX # 54 SUMAVEL DosePro 54 Cloretazine ® 54 Saforis 54 Nexavar ® 54 Genasense ® oblimersen 54 Bazedoxifene 54 ISTODAX 54 Hsp# Inhibitor 54 Advexin 54 REVLIMID R 54 Amigal TM 54 Keppra ® XR 54 BEMA Granisetron 54 Serostim ® 54 vapreotide acetate 54 denufosol 54 Vitrasert R 54 Files IND 54 mifamurtide 54 PRT# 54 ZEFTERA TM Zevtera TM 54 Phase 2b 54 ® decitabine 54 ZYBRESTAT 54 torezolid phosphate 54 Sanctura XR 54 cintredekin besudotox 54 virus HCV protease inhibitor 54 aldehyde dehydrogenase ALDH2 deficiency 54 Increlex TM 54 QuadraSphere 54 metastatic sarcomas 54 drug pipeline TAFA# 54 Pruvel 54 baminercept 54 sorafenib tablets 54 Telaprevir 54 SPL# Gel vaginal microbicide 54 CCR5 antagonist 54 orBec 54 daclizumab 54 Loramyc ™ 54 Nabi HB Intravenous 54 Romidepsin 54 Cimzia ® certolizumab pegol 54 lorvotuzumab mertansine 54 apricitabine 54 Fabry Disease 54 Arikace 54 Telavancin 54 steroid refractory GvHD 54 CIP TRAMADOL ER 54 including eniluracil ADH 54 mTOR inhibitor 54 JAK inhibitor 54 Sutent sunitinib 54 Phase 2b clinical 54 hereditary angioedema 54 Brilique 54 paliperidone palmitate 54 SUTENT 54 Initiates Phase III 54 Ridaforolimus 54 PHX# 54 Multaq R 54 Ranolazine 54 Golimumab 54 registrational studies 54 Liberte TM 54 Angiox 54 PEGylated Fab fragment 54 Oral BDP 54 Sanvar R 54 Carfilzomib 54 mTOR kinase 54 sodium Injection 54 Loramyc R 54 non alcoholic steatohepatitis 54 Zavesca r 54 Vernakalant 54 FavId 54 Ixempra 54 MT# MEDI 54 SinuNase TM 54 proteasome inhibitor 54 Fingolimod 54 Viviant 54 SEBIVO 54 Anthim 54 otelixizumab 54 GTC recombinant form 54 Cardiac Cryoablation System 54 oral iron chelator 54 Clolar 54 ZACTIMA 54 sNDA submission 54 Increlex R 54 Exherin TM 54 INCB# [002] 54 CNTO 54 Nexavar sorafenib 54 temsirolimus 54 Demonstrates Significant 54 Gencaro 54 cancer neuroendocrine tumor 54 Phase 2a Clinical Trial 54 methylnaltrexone bromide 54 Virulizin ® 54 HDAC Inhibitor 54 interferon gamma 1b 54 Kamada AAT 54 BENLYSTA TM 54 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 54 oral cladribine 54 Bayer Nexavar 54 liposomal formulation 54 EDEMA3 54 refractory gout 54 Expanded Indication 53 faropenem medoxomil 53 Aloxi R 53 alogliptin 53 edoxaban 53 Drug Submission 53 davunetide 53 Premarket Approval PMA 53 Clevudine 53 Phase 2b study 53 DAVANAT ® 53 Exenatide LAR 53 Shigamabs ® 53 Gleevec imatinib 53 Trofex 53 XIAPEX 53 Arcalyst 53 Product Designation 53 Zorbtive TM 53 cinacalcet HCl 53 indolent NHL 53 topical anti infective 53 thymalfasin 53 Phase III clinical trials 53 Dapagliflozin 53 Prestara 53 XIAPEX ® 53 Zytiga 53 Alair System 53 DR Cysteamine 53 zanolimumab 53 Oracea ® 53 Navelbine ® 53 Glybera R 53 systemically administered 53 Initiate Phase 53 treat GI GVHD 53 Emezine 53 Ruconest 53 Rescula 53 LymphoStat B TM 53 Junovan TM 53 Gabapentin GR 53 CYT# potent vascular disrupting 53 Clolar ® 53 % uracil topical 53 corticotropin injection 53 Syndrome LEMS 53 FRDA 53 vascular disrupting agent 53 AZILECT R 53 Exelixis XL# 53 JAK Inhibitor 53 Phase IIIb 53 Achieves Primary Endpoint 53 IND Filing 53 Annamycin 53 solifenacin succinate 53 OncoGel 53 severe oral mucositis 53 bafetinib 53 SUTENT ® 53 Complete Response Letter 53 albinterferon alfa 2b 53 approvable letters 53 Reports Preclinical Data 53 TMC# [002] 53 Pegloticase 53 DOR# 53 Somatuline Autogel 53 Valortim TM 53 orally administered inhibitor 53 ridaforolimus 53 advanced carcinoid 53 Bioral ® 53 Phase IIb trial 53 Bioral Amphotericin B 53 Phase Ib clinical trials 53 GvHD 53 candidate deforolimus 53 Solzira TM 53 Dupuytren contracture 53 Phase 1b trial 53 PGL# 53 volociximab 53 deforolimus 53 Lenocta TM 53 Tofacitinib 53 sNDAs 53 HP Acthar Gel repository 53 TKB# 53 Androxal ® 53 granted orphan medicinal 53 hereditary deficiency 53 MoxDuo IR 53 injectable formulation 53 Spiegelmer ® 53 Grants Orphan Drug 53 tocilizumab 53 LUCASSIN 53 pirfenidone 53 markets Gelclair R 53 synthetic lipoglycopeptide antibiotic 53 GAMMAGARD 53 TG# [003] 53 peripherally acting 53 Kuvan TM sapropterin 53 Cushing Syndrome 53 investigational oral inhibitor 53 TRANSDUR ® 53 zileuton IV 53 Phase #/#a 53 interferon beta 1b 53 Phase 2a Study 53 chronic immune thrombocytopenic 53 investigational compound 53 Abiraterone acetate 53 ONGLYZA ™ 53 faropenem 53 arterial thrombosis 53 angiogenesis inhibitor 53 biologic therapy 53 obatoclax 53 Phase 1b 53 FUSILEV ® 53 RELISTOR ® 53 Receives Milestone Payment 53 SPRYCEL ® 53 Positive Opinion 53 ELIQUIS 53 inhaled liposomal ciprofloxacin 53 Gleevec imatinib mesylate 53 pulmonology portfolio 53 CDP# 53 treat lupus renal 53 Ilaris 53 Urocidin 53 thetreatment 53 ELADUR ™ 53 Cimzia certolizumab pegol 53 docetaxel Taxotere ® 53 Phase IIB 53 ATL# [001] 53 Oral Calcitonin 53 Certican 53 EpiCept NP 1 53 refractory CLL 53 EVIZON TM 53 Impax ANDA 53 postherpetic neuralgia 53 Onco TCS 53 Votrient 53 vismodegib 53 RAPAFLO 53 Telatinib 53 abatacept Orencia 53 DU #b 53 pancreatic insufficiency 53 Tezampanel 53 BAL# [002] 53 R#/MEM 53 Mylan Receives Approval 53 ORENCIA R 53 antibody MAb 53 Aflibercept 53 SFDA approval 53 AEG# 53 Ciclesonide 53 CLIA waiver 53 Proquin XR 53 Mipomersen 53 Allovectin 7 ® 53 Angiox ® 53 Market Approval PMA 53 NDA resubmission 53 NEBIDO 53 PEG PAL 53 CVBT #H 53 ganetespib 53 Revimmune 53 Phase III Clinical Trials 53 supplemental biologics 53 Ambrisentan 53 ISO Vorin TM 53 BCG refractory carcinoma 53 sunitinib Sutent 53 MKC# MT 53 Ferumoxytol 53 SUMAVEL 53 JAK2 Inhibitor 53 seliciclib CYC# 53 oral methylnaltrexone 53 rFVIIIFc 53 Project QTDP 53 BEMA Fentanyl 53 Xcytrin R 53 Vimpat R 53 AMITIZA R 53 Exocrine Pancreatic Insufficiency 53 velafermin belinostat 53 abiraterone acetate 53 Phase 2a Trial 53 chronic eosinophilic leukemia 53 Trovax 53 candidate TNFerade biologic 53 PMA submission 53 Abstral 53 ELADUR 53 nonclinical studies 53 Submits NDA 53 REMINYL ® 53 naproxen esomeprazole magnesium 53 RSR# 53 Campath alemtuzumab 53 sodium thiosulfate STS 53 Receives Complete Response 53 erlotinib Tarceva ® 53 crofelemer 53 Omapro 53 THELIN 53 cerebral oximeter available 53 granted Fast Track 53 investigational monoclonal antibody 53 prokinetic agent 52 Cerepro ® 52 ponatinib 52 PROVENGE sipuleucel T 52 briakinumab 52 Fx #A 52 JAK1 52 adalimumab Humira 52 Fodosine TM 52 Targretin 52 ProSavin 52 IBS C 52 Excellarate TM 52 ONSOLIS 52 P#X# antagonist 52 ambrisentan 52 TRANSDUR Sufentanil 52 OvaRex ® MAb 52 Metastatic Colorectal Cancer 52 idiopathic thrombocytopenic purpura ITP 52 MONOVISC 52 Inhalation Aerosol 52 TKM ApoB 52 Cimzia ® 52 AAG geldanamycin analog 52 Loramyc ® 52 Acute Radiation Syndrome ARS 52 Phase 2a clinical 52 FDA Clearance 52 pralatrexate injection folate analogue 52 Cetrorelix 52 ONCASPAR 52 axitinib 52 Serdaxin 52 candidates bavituximab 52 AERx iDMS 52 Arranon 52 RHUCIN 52 MGd 52 HepaSphere 52 VALSTAR 52 unique alkylating agent 52 NV1FGF 52 vilazodone 52 Laquinimod 52 TOLAMBA 52 PREOS 52 Cintredekin besudotox 52 Lambert Eaton Myasthenic 52 Clinical Study 52 Phase III confirmatory 52 rhC1INH 52 hyperphenylalaninemia HPA due 52 Jevtana 52 JAK2 inhibitor 52 immune idiopathic thrombocytopenic 52 Subpart E 52 successfully commercialize Iluvien 52 CONBRIZA 52 Submits Response 52 OLEPTRO 52 rFVIIa 52 Campath ® 52 PrevOnco 52 humanized anti 52 Combination REOLYSIN R 52 cardio renal 52 Clofarabine 52 STELARA TM 52 IMiDs 52 ONTAK 52 ospemifene 52 ORE# 52 Phase 2b clinical trials 52 treat chronic sinusitis 52 rasagiline tablets 52 miconazole Lauriad R 52 Sprycel dasatinib 52 CIMZIA r 52 TroVax ® 52 novel VDA molecule 52 PI3K/Akt pathway inhibitor 52 Triapine 52 midstage studies 52 erlotinib Tarceva R 52 fostamatinib 52 Saphris 52 Horizant 52 sapacitabine 52 valtorcitabine 52 phase IIa 52 CAMPATH R 52 IDE Investigational Device Exemption 52 arsenic trioxide injection 52 oral FTY# 52 Fibrin Pad 52 Cethrin 52 Cinryze ™ 52 Rotarix R 52 product platforms AZX# 52 canakinumab 52 nanofiltered plasma derived 52 motexafin gadolinium Injection 52 Cardio Vascu Grow 52 ATPace TM 52 Li Fraumeni Syndrome 52 Hydroxyurea 52 mild vasodilator 52 visilizumab 52 CUBICIN 52 Simulect 52 Preclinical studies suggest 52 Staphylococcus aureus Polysaccharide Conjugate 52 CR# vcMMAE 52 5 lipoxygenase inhibitor 52 mitogen activated ERK kinase 52 subcutaneously administered 52 nasal calcitonin product 52 purpura ITP

Back to home page